阿卡波糖联合诺和锐30治疗肝源性糖尿病的疗效观察

摘要

目的：观察阿卡波糖联合诺和锐30治疗肝源性糖尿病的疗效。方法肝源性糖尿病患者46例，随机分为两组，每组23例，治疗组在早、晚餐前30 min皮下注射诺和锐30（12～40 U/d）及口服阿卡波糖片50 mg，1～3次/d；对照组仅给予诺和锐30治疗，用法与治疗组相同。比较两组空腹血糖（ FBG）、餐后2 h血糖（2hPG）及糖化血红蛋白（HbA1c）水平。结果两组患者治疗后FBG、2hPG及HbA1c水平与治疗前相比均明显下降（ P＜0．05）；治疗后两组FBG水平比较，差异无统计学意义（ P＞0．05）；治疗后，治疗组2hPG及HbA1 c水平均明显低于对照组（ P均＜0．05）。结论阿卡波糖联合诺和锐30治疗肝源性糖尿病，可以有效降低患者的2hPG、HbA1 c水平。%Objective To observe the effect of acarbose combined with insulin aspart 30 on hepatogenic diabetes . Methods Forty-six patients with hepatogenic diabetes were randomly divided into two groups ,with 23 cases in each group.The treatment group was given subcutaneous injection of insulin aspart 30(12-40 U/d) and oral acarbose tablet (50 mg) 30 minutes before breakfast and dinner ,one to three times a day .The control group was given insulin aspart 30 alone,the method of medication was as same as that conducted in the treatment group .The levels of fast blood glucose (FBG),2 hours plasma glucose(2hPG) and hemoglobin A1c(HbA1c) were compared between two groups .Results The levels of FBG,2hPG and HbA1 c decreased significantly in both groups after treatment in contrast with those before treatment (P<0.05).There was no significant difference in the level of FBG between two groups (P>0.05).The levels of 2hPG and HbA1 c in the treatment group were significantly lower than those in the control group after treatment ( all P<0 .05 ) . Conclusion Acarbose combined with insulin aspart 30 applied to patients with hepatogenic diabetes can effectively reduce the levels of 2hPBD and HbA1 c.